Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells

Table 1 Comparison of clinical parameters between patients with positive or negative SRPK1 expression

Clinical Parameters	Overall	SRPK1-	SRPK1 +	P-value
N	41	15	26
Gender				0.381
Male	28	12	16
Female	13	3	10
Age				0.382
≥ 60	10	2	8
< 60	31	13	18
Ann Arbor Stage				0.730
I/II	26	9	17
III/IV	15	6	9
Serum LDH (U/l)				0.678
Normal	28	12	16
Increased	13	3	10
IPI				0.730
0 ~ 1	26	9	17
≥ 2	15	6	9
Ki-67				0.018
< 60	15	9	6
≥ 60	26	6	20
Serum β2 microglobulin (μg/ml)				0.017
Normal	20	11	9
Increased	21	4	17
B symptoms				0.607
Absent	24	8	16
Present	17	7	10
BM involvement				0.727
Yes	8	2	6
No	33	13	20
Sensitive to cisplatin				0.033
Yes	11	5	6
No	13	1	12

B symptoms: unintentional weight loss of > 10% of normal body weight over a period of six months or less, fever > 38 °C for more than three days without any evident cause other than lymphoma, and human drenching night sweats
Sensitive to cisplatin: Patients achieved complete remission or partial response after cisplatin-containing chemotherapies, which include DDGP regimen chemotherapy (dexamethasone, cisplatin, gemcitabine, and pegaspargase) and IPGDP regimen chemotherapy (ifosfamide, pegaspargase, gemcitabine, cisplatin, and dexamethasone)

ISSN: 1471-2407